PTC Therapeutics Reports Second Quarter 2019 Financial Results and Provides a Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Broadcom secures role as key Apple supplier with chip deal through 2031
PTC Therapeutics (PTCT) Misses Q2 EPS by 17c, Revenues Beat
August 6, 2019 5:25 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($0.75), $0.17 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $85.5 million versus the consensus estimate of $78.64 million.
Second quarter 2019 financial highlights:
Total revenues were $85.5 million for the second quarter of 2019, compared to $68.7 million for the second quarter of 2018.Translarna net product revenues were $57.8 million for the second quarter of 2019, compared to $47.8 million for the second quarter of 2018. These results reflect the expanded commercialization of Translarna.Emflaza net product revenues were $27.6 million for the second quarter of 2019, compared to... More